RNN Rexahn Announces Initial Results from Phase I Trial of SupinoxinTM (RX-5902) for Solid Cancer Tumors http://finance.yahoo.com/news/rexahn-announces-initial-results-phase-120000064.html?soc_src=mediacontentstory